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Key messages
 ► The pharmacist-led intervention secured a minimal-
ly important difference (MID) in Asthma Control Test 
(ACT) score.
 ► The proportion of patients on target (MID of 3 points) 
improved at 3-month postintervention and kept im-
proving after 6 months.
 ► Securing MID in ACT score was linked with cost 
reduction and quality-adjusted life years increase 
when moving from not controlled to partially con-
trolled, or from partially to fully controlled.
AbstrAct
Introduction A key priority in asthma management is 
achieving control. The Asthma Control Test (ACT) is a 
validated tool showing a numerical indicator which has 
the potential to provide a target to drive management. 
A novel pharmacist-led intervention recently evaluated 
and introduced in the Italian setting with a cluster 
randomised controlled trial (C-RCT) showed effectiveness 
and cost-effectiveness. This paper evaluates whether 
the intervention is successful in securing the minimally 
important difference (MID) in the ACT score and provides 
better health outcomes and economic savings.
Methods Clinical data were sourced from 816 adult 
patients with asthma participating in the C-RCT. The 
success of the intervention was measured looking at the 
proportion of patients reaching MID in the ACT score. 
Different levels of asthma control were grouped according 
to international guidelines and graded using the traffic 
light rating system. Asthma control levels were linked 
to economic (National Health Service (NHS) costs) and 
quality-adjusted life years outcomes using published data.
results The median ACT score was 19 (partially 
controlled) at baseline, and 20 and 21 (controlled) at 
3-month and 6-month-follow up, respectively (p<0.01). 
The percentage of patients reaching MID at 3 and 6 
months was 15.8% (129) and 19.9% (162), respectively. 
The overall annual NHS cost savings per 1000 patients 
attached to the shift towards the MID target were equal to 
€346 012 at 3 months and increased to €425 483 at 6 
months. Health utility gains were equal to 35.42 and 45.12 
years in full health gained, respectively.
Discussion The pharmacist-led intervention secured the 
MID in the ACT score and provided better outcomes for 
both patients and providers.
IntroDuctIon
the clinical and economic burden of asthma
Recently updated information from the 
WHO1 has confirmed that asthma is still one 
of the major non-communicable diseases, 
but that medication can control asthma and 
appropriate management can enable people 
with asthma to enjoy a good quality of life. 
Fink and Rubin2 have suggested that manage-
ment of chronic airways disease is 10% medi-
cation and 90% education.
The prevalence of asthma has been 
increasing since the late 1990s, and it has 
been estimated that about 400 million people 
will suffer from asthma by 2025.3 4 Asthma 
accounts for an economic loss of €72 billion 
annually in the 28 countries of the Euro-
pean Union5; this includes the annual costs 
of healthcare (about €20 billion), the loss of 
productivity for patients (€14 billion) and 
a monetised value of disability-adjusted life 
years loss of €38 billion. In Italy the economic 
burden of asthma which relates to the degree 
of control is approximately €5 billion 
annually. Studies have shown that asthma 
control has a direct impact on costs6 7 and 
quality of life,8 and that there is a clear link 
between adherence to treatment and asthma 
control.9 The Global Initiative for Asthma 
(GINA)10 suggested that the long-term goals 
of asthma management are to achieve good 
symptom control and to minimise future risk 
of exacerbation, introducing the concept of 
control-based management, meaning that 
the treatment is adjusted in a continuous 
cycle of assessment, treatment and review 
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of patients’ response in terms of control and therefore 
future risk (attacks and side effects). A key priority is the 
development of a simple and effective intervention for 
improving asthma control,11 which allows achievement 
of better socioeconomic and health-related quality of life 
outcomes.12 13
An effective and cost-effective intervention for patients with 
asthma: background evidence from a c-rct
An innovative pharmacist-led intervention for patients 
with asthma was delivered and evaluated as part of a 
cluster randomised controlled trial (C-RCT) conducted 
in 15 of the 20 regions of Italy between September 2014 
and July 2015.14 It involved 1263 patients with asthma and 
283 pharmacists across the territory. The development of 
the intervention was informed through literature review 
conducted between 2010 and 2013, which aimed to 
identify studies reporting pharmacist-led intervention in 
patients with asthma around the world. The review looked 
at the following countries: Australia,15 16 Belgium,17 
Canada,18 Denmark,19 Finland,20 21 Germany,22 23 Malta,24 
New Zealand,25 Spain,26 UK27 28 and USA.29 The review 
included randomised and non-randomised studies and 
allowed identification of the strengths and limitations of 
each study. Eighteen key points were identified during 
the review and informed the development of the pharma-
cist-led intervention, which was informed and retrospec-
tively mapped to the Medical Research Council (MRC) 
framework30 for complex intervention. This intervention 
represents a bespoke, systematic, structured, face-to-face, 
pharmacist-led consultation, covering asthma symptoms, 
medicines used, patients’ attitude towards medicines 
and self-reported adherence, plus recording of pharma-
cist-identified pharmaceutical care issues (PCIs).14
Community pharmacists were stratified by regions 
and randomly allocated to group A, who were trained in 
and delivered the intervention at baseline, and group B, 
who received training and delivery 3 months later. The 
procedure was conducted using a computerised random 
number generation in blocks of 10. Each pharmacist 
recruited up to five patients, and both groups (A and 
B) were followed for 9 months. Data were collected at 
3-month intervals (at baseline (T0); at 3 months (T3); at 
6 months (T6); and at 9 months (T9)).
The primary outcome was asthma control, assessed 
using the Asthma Control Test (ACT) score (ACT ≥20 
represents good control). The secondary outcomes were 
(1) the number of active ingredients, (2) adherence and 
(3) cost-effectiveness compared with usual care. Blinding 
was not possible for either pharmacists or patients. The 
assessment of outcomes was conducted by a researcher 
blind to group allocation.
The population overall included more women than 
men, and the proportion of patients with not-con-
trolled asthma was different between the two groups 
(A and B), with a median ACT score at baseline of 
19 and 18 (see online supplementary material 1). 
Clinical outcome data (ACT score) were not normally 
distributed. Mann-Whitney U test was used to assess 
the ACT score difference between groups before the 
intervention. Wilcoxon signed-rank test was applied to 
the pooled sample to assess the ACT score within the 
group at different time points. The power and sample 
size calculation was conducted a priori including four 
different scenarios.31
For cost analysis we used Vervloet et al6 cost data on 
scheduled healthcare visits to their usual physician 
and specialist, unscheduled healthcare asthma-related 
inpatient admissions, emergency visits and emergency 
contacts with a physician. Healthcare provider costs were 
estimated from an Italian National Health Service (NHS) 
perspective. Italian societal costs were sourced from 
Accordini et al.7 Health outcome data, in terms of quali-
ty-adjusted life year (QALY), a utility measure of disease 
burden, including both the quality and the quantity of 
life, were also sourced from the literature looking at 
published evidence for the Italian population.8 The cost 
for delivering the Italian Medicines Use Review (I-MUR) 
service per visit per patient was estimated as €40; calcu-
lations were based on an average cost of similar services 
provided in different countries (eg, Canada, Switzerland, 
UK and USA). All cost data were actualised from 2005 to 
2015.
The average annual cost (NHS and society) and 
utility estimates per patient across groups were calcu-
lated looking at the three asthma control categories 
(not controlled, partially controlled and controlled) as 
presented in the framework of analysis below (see the 
Materials and methods section) and linked to the C-RCT 
data looking at the patient-level ACT scores as reported 
at three time points (T0, T3 and T6).
The summary cost-effectiveness statistic calculated 
was the incremental cost-effectiveness ratio (ICER). 
Uncertainty and variation around the ICER mean were 
represented by the cost-effectiveness acceptability curve, 
obtained by resampling the data 1000 times to generate 
a mean cost and life year or QALY gain from each group, 
using a non-parametric bootstrap approach. The propor-
tion of resampled data sets for which the calculated ICER 
lies below a given threshold was interpreted as the prob-
ability that the ICER of the intervention is below that 
threshold.
The key results of the C-RCT showed that the interven-
tion was:
 ► Effective: The median ACT score was 19 (partially 
controlled) before the intervention, 20 (controlled) 
at 3 months after the intervention and 21 at 6 months 
(p<0.01; see online supplementary material 1). The 
OR for improved asthma control was 1.76 (95% CI 
1.33 to 2.33) in patients who received the interven-
tion versus the ones who did not, and the number 
needed to treat was 10 (95% CI 6 to 28).
 ► Cost-effective: The probability of the intervention 
being more cost-effective than usual care was 100% 
at 9 months. More details are reported elsewhere.14
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The intervention also had a positive impact on the 
following:
 ► The optimisation of the number of asthma active 
ingredients used by patients, which was reduced by 
8%, and patients’ self-reported adherence to medica-
tion, which increased by 40%.
This study had several limitations, among which the 
evaluation of patients’ adherence was not conducted 
using a validated tool, but with two questions, for brevity, 
used also in the English MUR template. The economic 
evaluation was conducted using secondary data because 
primary data were not available due to a tight budget.
Although the C-RCT evaluation showed a positive 
impact of the pharmacist-led intervention on asthma 
control in terms of improved ACT score (defined as 
change from not controlled/partially controlled to 
controlled asthma), the researchers did not measure 
whether patients who improved their asthma control 
reported the smallest difference in ACT score that 
represents a clinically significant change (ie, the mini-
mally important difference, MID) of 3 points in the ACT 
score. The MID in the ACT score of 3 points is a measure 
identified by Schatz et al,32 who suggested that a 3-point 
difference or change in ACT is clinically meaningful and 
such a target should be considered when evaluating the 
clinical performance of asthma interventions.
Aims and research questions
The focus of the main C-RCT evaluation was to measure 
the impact of the pharmacist-led intervention on asthma 
control (in terms of gains in median ACT score) and, 
following this, possible benefit in terms of cost-effec-
tiveness (see online supplementary material 1 and else-
where14). The purpose of this paper is to take the C-RCT 
evaluation a step further and measure the impact of the 
pharmacist-led intervention on MID in asthma control 
(looking at the proportion of patients reaching a 3-point 
improvement (MID) in the ACT score). Given the posi-
tive outcomes of the C-RCT in terms of both cost-effec-
tiveness (cost per QALYs) and cost savings for the NHS, 
we also looked at possible benefits of reaching clinical 
MID, in terms of both health outcomes (QALYs) for the 
patient and economic savings for the healthcare provider.
The key research questions were the following:
 ► Is the pharmacist-led intervention provided to 
patients with asthma effective in securing the MID in 
the ACT (assessed by a 3-point difference in the ACT 
score)?
 ► What is the impact of MID on patients’ quality of life 
and costs to the healthcare provider?
MAterIAls AnD MethoDs
The total C-RCT patient population included in the 
intention-to-treat analysis was 1263.14 A subsample of 
those (n=816) was used for this analysis (see the C-RCT 
per-protocol approach).14 The proportion of patients on 
target was compared between groups at baseline and at 
3 and 6 months after. Categorical variables were analysed 
using χ2 test for independence.
In the following sections we present the outcome 
measures and the framework of analysis adopted. Details 
on the methods uncertainty around cost and QALY 
parameters are reported above and elsewhere.14
outcome measures
The primary outcome was the proportion of patients who 
reached a 3-point improvement (MID) in the ACT score.
The following were the secondary outcomes linked to 
the MID:
 ► Health outcome in terms of QALY.
 ► Costs for the healthcare provider (NHS) to include 
the cost data on scheduled healthcare visits to their 
usual physician and specialist, unscheduled health-
care asthma-related inpatient admissions, emergency 
visits and emergency contacts with a physician. Costs 
were estimated from an Italian NHS perspective.
the framework of analysis
Different levels of asthma control were grouped according 
to international guidelines33 and graded using the traffic 
light rating system (figure 1). Following this, the colour-
coded asthma control levels were linked to costs (NHS 
costs) and health outcome (QALY utility) data using the 
multidimensional data matrix presented in figure 2.
The average annual cost and utility estimates per 
patient were extrapolated for not controlled, partially 
controlled and controlled patients as follows:
 ► €2727 (95% CI 863 to 4009); €870 (95% CI 306 to 
1279); and €394 (95% CI 127 to 579).
 ► QALY: 0.62 (95% CI 0.60 to 0.64); 0.71 (95% CI 0.70 
to 0.72); and 0.91 (95% CI 0.90 to 0.92).
Overall the traffic light rating system allowed the 
following:
 ► Colour code-specific stages of asthma control 
(RED) not controlled (ACT scores 5–14), YELLOW 
partially controlled (ACT scores 15–19) and GREEN 
controlled (ACT scores 20–25), defined in terms of 
clinical, economic and health outcome measures 
(figure 1).
 ► Monitor possible changes in asthma control using 
a typical sequence of traffic light colour phases (eg, 
the more asthma is under control (moving from RED 
to YELLOW, and then GREEN) where less money is 
spent (in terms of annual costs per patient incurred 
by the NHS) and also more people are able to experi-
ence better health) (figure 2).
Specific gains (in costs and health utility) when 
shifting between different asthma control groups are 
described in table 1. In order to test whether a gain in 
ACT score equal to 3 points in ACT score (MID) could 
have an impact in terms of improved health outcome for 
the patients (QALY) and cost savings for the healthcare 
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Figure 1 The asthma control groups and their traffic light rating system. The Asthma Control Test (ACT) is a five-item 
questionnaire that defines three levels of asthma control according to the Global Initiative for Asthma guidelines. Three 
specific ranges of ACT sources are reported in the figure.37 Euroqol-5D, Euroqol 5 dimensions.
Figure 2 The framework of analysis. Cost for the healthcare provider (National Health Service (NHS)): the cost data 
on scheduled healthcare visits to their usual physician and specialist, unscheduled healthcare asthma-related inpatient 
admissions, emergency visits and emergency contacts with a physician. Utility score: the gains in health utility (years in full 
health saved) measured using the Euroqol-5D score, where its values lie on a scale on which full health has a value between 
1 (full health) and 0 (dead).8 For the purpose of this testing, the economic data were sourced from Vervloet et al.6 All cost data 
were actualised from 2005 to 2015. Euroqol 5D, Euroqol 5 dimensions.
provider (NHS), we considered five different scenarios, 
described in table 2.
The ACT scores obtained from the pooled data set 
(groups A and B before receiving the pharmacist-led 
intervention)14 34–36 were considered for analysis, and 
the proportion of individuals who met the MID target 
was calculated after 3-month and 6-month follow-up. 
A reference population of 1000 patients with asthma 
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Table 2 Possible asthma control cases when securing an MID in asthma control
Possible cases Description 
Possible shifts
(current to target scenario)
Current 
scenario (ACT)
Target 
scenario (ACT)
Asthma is not controlled and a gain in ACT score equal to 
3 points:
1 RED to RED
  
Did not change the asthma control status—still not 
controlled.
5–10 8–13
2 RED to YELLOW
  
Did change the asthma control status—from not 
controlled to partially controlled.
11–14 14–17
Asthma is partially controlled and a gain in ACT score 
equal to 3 points:
3 YELLOW to YELLOW
  
Did not change the asthma control status—still partially 
controlled.
15–16 18–19
Asthma moved from partially controlled to controlled and 
a gain in ACT score equal to 3 points:
4 YELLOW to GREEN
  
Did change the asthma control status—from partially 
controlled to controlled.
18–19 20–21
Asthma is controlled and a gain in ACT score equal to 3 
points:
5 GREEN to GREEN
  
Did not change the asthma control status—always 
controlled.
20–21 ≥23
Possible shifts: a series of shifts in care landscape were considered towards a target scenario where a patient with asthma experienced a 
clinically significant change in ACT score equal to the MID of 3 points in ACT score.
ACT, Asthma Control Test; MID, minimally important difference.
Table 1 A shift towards clinical target in asthma control (MID): impact on asthma control, cost savings and gains in health 
utility (annual estimates per patient)
Possible shifts
(current to target scenario) ACT
Costs for the 
healthcare 
provider Utility score
Current 
scenario (ACT)
Target scenario
(ACT)
Gain in asthma 
control (fixed, 
MID)
Annual saving 
(2015 euros, per 
patient)
Gain in health 
utility
(years in full 
health saved)
1 RED to RED
  
5–10 8–13 3 NA NA
2 RED to YELLOW
  
11–14 14–17 3 −1857 (95% CI 
−2414 to −1393)
0.09 (95% CI 
0.088 to 0.092)
3 YELLOW to YELLOW
  
15–16 18–19 3 NA NA
4 YELLOW to GREEN
  
18–19 20–21 3 −2333 (95% CI 
−3033 to −1750)
0.29 (95% CI 0.28 
to 0.30)
5 GREEN to GREEN
  
20–21 ≥23 3 NA NA
Possible shifts:a shift in care landscape was considered towards a target scenario where a patient with asthma experienced a clinically 
significant change in ACT score equal to the MID of 3 points in ACT score.
ACT, Asthma Control Test; MID, minimally important difference; NA (not associated), no change in outcome was captured.
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Figure 3 Proportion of patients with asthma on target, annual cost savings and utility gains when securing clinical target in 
asthma control (minimally important difference) with the pharmacist-led intervention. Population considered=1000 patients 
with asthma. QALY, quality-adjusted life years. Part A, results at 3 months; Part B, results at 6 months.
was established, and the number of patients on target 
was calculated for the different shifts. For those who 
reached the MID target of 3 points, the annual cost 
saving and utility gains were computed accordingly.
results
Patients demographic and Act scores
The number of patients included in this analysis was 816 
(pooled sample A intervention+B control; see online 
supplementary material 1). No statistical differences were 
identified between A and B groups before the interven-
tion. In the pooled sample the median ACT score before 
the intervention was 19, at 3 months after the interven-
tion 20 (16–23) and at 6 months 21 (17–23). The differ-
ences were statistically significant (p<0.01).
the pharmacist-led intervention provided positive results 
according to the MID
The proportion of patients who were on MID target and 
reached the GREEN group at 3 and 6 months moved 
from 15.8% to 19.9%, respectively. Online supplementary 
material 2 presents the subsample of people who met a clin-
ically significant change in ACT score equal to the MID of 3 
points for the five different scenarios described in table 2.
When looking at a cohort of 1000 patients with asthma, 
the overall cost savings attached to the shift towards the 
MID target (ie, the 349 patients who moved towards better 
control of their asthma and closed the gaps between 
RED-YELLOW (150 patients) and YELLOW-GREEN 
(199 patients)) were equal to €346 012 at 3 months and 
increased to €425 483 at 6 months. Health utility gains 
translated into additional 35.42 and 45.12 years in full 
health gained. Figure 3 presents the annual cost savings 
and utility gains for the five different cases described in 
table 2. The changes from RED to YELLOW (shift 2) 
and YELLOW to GREEN (shift 4) presented the highest 
benefits in terms of % on target, cost savings and utility 
gains at both 3 and 6 months (figure 3).
DIscussIon
This analysis has demonstrated that the pharmacist-led 
intervention14 can secure an MID in the ACT and in 
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doing so improve patients’ health outcome as well as 
reduce costs to the NHS. The framework approach to 
data analysis presented in this paper allows the evaluation 
of the impact of MID on the ACT score in terms of cost 
savings for the healthcare provider and gains in health 
outcome for patients.
clinical implications
The introduction of the pharmacist-led intervention 
and its success in securing a 3-point MID in ACT showed 
that the economic and utility benefits of better asthma 
control are evident when shifting from RED-YELLOW 
and YELLOW-GREEN. Given that the costs associ-
ated with controlled asthma are lower than those for 
managing uncontrolled asthma, any change between not 
controlled to partially controlled (RED-YELLOW) had 
greater impact on effectiveness and cost-effectiveness 
than partially controlled-controlled (YELLOW-GREEN) 
at 3–6 months of follow-up.
The results showed that the pharmacist-led interven-
tion could promote a shift in current practice towards 
better asthma control, and this was confirmed by the 
C-RCT evaluation.14 Original C-RCT data showed that the 
ACT score improved at 3 months after the intervention 
and went up again at 6 months, suggesting the sustain-
ability of the results.
economic implications
The economic evaluation showed that meeting the 3-point 
MID target can be cost saving for the healthcare provider, 
and similar results are confirmed in the literature. For 
example, Schatz et al32 showed that on average a decrease 
in asthma control of 3 points in the ACT was associated 
with a subsequent 76% increased risk of excess short-acting 
β-agonist use and a 33% increased risk of exacerbations with 
significant impact on the socioeconomic costs. Vervloet et 
al6 showed that the average cost of asthma management 
was more than six times higher among patients at the 
lower levels of the ACT scale with derived ACT score <15 
(see figure 2), compared with patients under control, that 
is, with a derived ACT score of ≥20. A systematic review13 
looking at the economic burden of asthma suggested that 
hospitalisation and medication were the most important 
drivers of healthcare costs, while work loss accounted for 
the greatest percentage of indirect costs. Moreover, a multi-
national cross-sectional survey has suggested that the ACT 
is a predictor of GINA guideline-defined asthma control.37 
Multiple strategies including, for example, education 
of patients and doctors, as well as regular follow-up, are 
required to reduce the economic impact of the disease on 
both direct and indirect costs. Patients’ education was indi-
cated as the most common PCI identified by pharmacists 
during the C-RCT project,14 where pharmacists followed 
up their patients for 9 months. As already mentioned Fink 
and Rubin2 suggested that the management of chronic 
airways disease is 10% medication and 90% education. This 
analysis of the MID confirmed that even an improvement 
of 3 points showed an important contribution in clinical, 
quality of life and economic terms.
strengths and limitations of the pharmacist–led intervention 
and the framework of analysis
The development of the pharmacist-led intervention 
was informed by the MRC framework. The interven-
tion proved to be an innovative and bespoke service for 
patients with asthma,14 supported by effective and cost-ef-
fective outcomes. An additional strength of the paper is 
the fact that the framework of analysis is based on the 
National Institute for Health and Care Excellence guide-
lines and constitutes an easy tool to monitor healthcare 
performance in terms of clinical, NHS costs and health 
utility outcomes. The same framework analysis was repli-
cated using a societal perspective (to include loss produc-
tivity at work),7 and similar cost-effective and cost saving 
results were confirmed (data are available from the 
authors on request).
The lack of C-RCT primary data on the economic 
and health outcome indicators was filled using alterna-
tive sources in the literature,6–8 still posing limitations in 
terms of generalisability of estimates, the lack of clarity 
about either the costing methodology adopted or the 
utility tariff used to calculate QALY, the components of 
the cost included (which did not include medication), 
and the bundle of care considered that may reflect old 
treatment practices (2004/2005), which are likely to 
have changed across time. Given the fact that cost and 
utility estimates were hard to find, a few pragmatic 
compromises were necessary in modelled approaches. 
A further limitation of this study is represented by the 
lack of economic and health outcome data on possible 
improvement of the MID within specific asthma control 
categories (eg, 3-point changes that lie within the red 
area (5–14) did not present any gain in NHS savings 
and QALYs). Unfortunately the secondary data sources 
used for this analysis provided aggregate information 
on the average economic and QALY impacts of asthma 
control (looking at the three categories not controlled, 
partially controlled and controlled), whereas these did 
not allow to have detailed information on the benefits 
attached to individual ACT scores and estimates for the 
individual indicators (such as exacerbations, non-elective 
admissions, visits to the general practitioner and so on). 
The effectiveness and cost-effectiveness of the pharma-
cist-led intervention were based on data collected in an 
experimental setting (C-RCT) with a focus on an adult 
population in Italy. Another limitation of this study is the 
potential unmeasured confounding effect that has not 
been captured in either the clinical or cost data due to 
the use of the per-protocol analysis approach. More data 
are needed to monitor the success of the intervention 
in real-world environment across different healthcare 
systems and populations. Other limitations of the phar-
macist-led intervention have been discussed elsewhere.14
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conclusIon
Clinicians and general practitioners looking after their 
patients with asthma (as well as their professional organi-
sations) can now evaluate the effect and impact of asthma 
control on clinical, health and costs outcomes, and 
measure the success of asthma control both in primary 
and secondary care. Pharmacists could use this evidence-
based approach for the provision of a pharmacist-led 
intervention which appears to be value for money and 
can align their services with those of other providers 
as members of the same healthcare professional team. 
Patients can achieve better asthma control and quality 
of life, even with a minimum gain of 3-point ACT score. 
Following discussions of the C-RCT findings with an 
audience of policy makers, commissioners and practi-
tioners in Italy,38 UK39 and Europe,40 41 it appears that 
this bespoke pharmacist-led intervention for patients 
with asthma presents a significant opportunity for success 
of improving asthma control if implemented in the real-
world setting.
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